Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder

被引:10
|
作者
Vataire, Anne-Lise [1 ]
Aballea, Samuel [1 ]
Antonanzas, Fernando [2 ]
Hakkaart-van Roijen, Leona [3 ]
Lam, Raymond W. [4 ]
McCrone, Paul [5 ]
Persson, Ulf [6 ]
Toumi, Mondher [7 ]
机构
[1] Creat Ceut, F-75008 Paris, France
[2] Univ La Rioja, Logrono, Spain
[3] Erasmus Univ, Rotterdam, Netherlands
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[5] Kings Coll London, London, England
[6] Swedish Inst Hlth Econ, Lund, Sweden
[7] Univ Lyon, Lyon, France
关键词
antidepressants; cost-effectiveness; depression; discrete event simulation; RESIDUAL SYMPTOMS; IMPACT; REMISSION; CITALOPRAM; COSTS; RISK;
D O I
10.1016/j.jval.2013.11.012
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: A review of existing economic models in major depressive disorder (MDD) highlighted the need for models with longer time horizons that also account for heterogeneity in treatment pathways between patients. A core discrete event simulation model was developed to estimate health and cost outcomes associated with alternative treatment strategies. Methods: This model simulated short- and long-term clinical events (partial response, remission, relapse, recovery, and recurrence), adverse events, and treatment changes (titration, switch, addition, and discontinuation) over up to 5 years. Several treatment pathways were defined on the basis of fictitious antidepressants with three levels of efficacy, tolerability, and price (low, medium, and high) from first line to third line. The model was populated with input data from the literature for the UK setting. Model outputs include time in different health states, quality-adjusted life-years (QALYs), and costs from National Health Service and societal perspectives. The codes are open source. Results: Predicted costs and QALYs from this model are within the range of results from previous economic evaluations. The largest cost components from the payer perspective were physician visits and hospitalizations. Key parameters driving the predicted costs and QALYs were utility values, effectiveness, and frequency of physician visits. Differences in QALYs and costs between two strategies with different effectiveness increased approximately twofold when the time horizon increased from 1 to 5 years. Conclusion: The discrete event simulation model can provide a more comprehensive evaluation of different therapeutic options in MDD, compared with existing Markov models, and can be used to compare a wide range of health care technologies in various groups of patients with MUD.
引用
收藏
页码:183 / 195
页数:13
相关论文
共 50 条
  • [21] Five-year outcome of major depressive disorder in primary health care
    Riihimaki, K. A.
    Vuorilehto, M. S.
    Melartin, T. K.
    Isometsa, E. T.
    PSYCHOLOGICAL MEDICINE, 2014, 44 (07) : 1369 - 1379
  • [22] TREATMENT PERSISTENCE WITH DULOXETINE AND HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER
    Liu, X.
    Tepper, P.
    Mullins, C. D.
    VALUE IN HEALTH, 2010, 13 (03) : A112 - A113
  • [23] Major Depressive Disorder in Iran: Epidemiology, Health Care Provision, Utilization, and Challenges
    Amin-Esmaeili, Masoumeh
    Shadloo, Behrang
    Rahimi-Movaghar, Afarin
    Ardestani, Seyed Mehdi Samimi
    Hajebi, Ahmad
    Khatibzadeh, Shahab
    Sharifi, Vandad
    Samadi, Roya
    Yasamy, Mohammad Taghi
    Zarghami, Mehran
    Farzadfar, Farshad
    Shahraz, Saeid
    ARCHIVES OF IRANIAN MEDICINE, 2022, 25 (05) : 329 - 338
  • [24] When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
    Jonathan Karnon
    Hossein Haji Ali Afzali
    PharmacoEconomics, 2014, 32 : 547 - 558
  • [25] When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES
    Karnon, Jonathan
    Afzali, Hossein Haji Ali
    PHARMACOECONOMICS, 2014, 32 (06) : 547 - 558
  • [26] Care pathways for people with major depressive disorder
    Strawbridge, R.
    Young, A.
    EUROPEAN PSYCHIATRY, 2022, 65 : S620 - S620
  • [27] Major Depressive Disorder: Treatment in Primary Care
    Schmidt, Leigh
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2020, 16 (09): : A19 - A19
  • [28] Care pathways for people with major depressive disorder
    Strawbridge, R.
    Zahn, R.
    Eberhard, J.
    Wasserman, D.
    Hegerl, U.
    Brambilla, P.
    Balazs, J.
    Caldas-de-Almeida, J.
    McCrone, P.
    Ulrichsen, A.
    Baltzis, S.
    Carli, V.
    Antunes, A.
    Schiena, G.
    Quoidbach, V.
    Boyer, P.
    Young, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 53 : S281 - S282
  • [29] Major depressive disorder, somatic pain, and health care costs in an urban primary care practice
    Gameroff, Marc J.
    Olfson, Mark
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (08) : 1232 - 1239
  • [30] COMBINING POINT CLOUD TECHNOLOGIES WITH DISCRETE EVENT SIMULATION
    Lindskog, Erik
    Berglund, Jonatan
    Vallhagen, Johan
    Berlin, Rolf
    Johansson, Bjorn
    2012 WINTER SIMULATION CONFERENCE (WSC), 2012,